Danielle Feigenbaum, MD
Neurology · Los Angeles, CANPI 1558621904
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 36 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Medtronic accounts for 87.0% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $682 and has fallen 96.4% since, to $25 in 2025. That places this record below the midpoint for neurology clinicians in CA, where the typical reported total is $885.
Across 36 payments — averaging $23.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$722
- SK Life Science, Inc.$37
- Pfizer$25
- AbbVie$23
- Acorda Therapeutics, Inc$22
- Travere Therapeutics, Inc.$2
Across 27 payments — averaging $6069.86 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amneal Pharmaceuticals LLC$72K
- UCB SA$64K
- Eli Lilly$27K
What the payments were for
- Speaking & faculty fees$223%
- Food & beverage$80697%
- Education$20%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 30 | $722 |
| SK Life Science, Inc. | 1 | $37 |
| Pfizer | 1 | $25 |
| AbbVie | 1 | $23 |
| Acorda Therapeutics, Inc | 1 | $22 |
| Travere Therapeutics, Inc. | 2 | $2 |
How this compares
$830 in reported general payments places this provider in the 45th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GammaplexImmun Glob G(Igg)/Gly/Iga 0-50 | 14 | $498,160 |
| GocovriAmantadine Hcl | 29 | $174,961 |
| IngrezzaValbenazine Tosylate | 16 | $129,005 |
| RytaryCarbidopa/Levodopa | 75 | $48,212 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 345 | $22,607 |
| Rasagiline Mesylate | 98 | $16,629 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 216 | $10,874 |
| Carbidopa | 17 | $8,198 |
| Entacapone | 36 | $5,434 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 49 | $1,690 |
| Donepezil Hcl | 92 | $1,557 |
| Pregabalin | 19 | $1,536 |
| Clozapine | 57 | $1,436 |
| AmantadineAmantadine Hcl | 31 | $1,138 |
| Propranolol Hcl | 50 | $1,080 |
Paid to pharmacies, not to this prescriber.
Other neurology in Los Angeles
- Perry ShiehLos Angeles$2.4M
- David LiebeskindLos Angeles$1.9M
- John SternLos Angeles$999K
- Jeffrey CummingsLos Angeles$918K
- Alan RapoportLos Angeles$808K
- Alon AvidanLos Angeles$505K
- Mark LewLos Angeles$450K
- Dawn EliashivLos Angeles$364K
- Richard LewisLos Angeles$309K
- Margaret BurnettLos Angeles$293K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.